US2007154912A1PendingUtilityA1

87 Human Secreted Proteins

63
Assignee: HUMAN GENOME SCIENCES INCPriority: Mar 21, 1997Filed: Dec 4, 2006Published: Jul 5, 2007
Est. expiryMar 21, 2017(expired)· nominal 20-yr term from priority
A61P 3/10A61P 7/06A61P 37/08A61P 9/12A61P 9/10A61P 37/06A61P 35/02A61P 35/00A61P 7/02A61P 37/04A61P 29/00A61P 3/02A61P 25/20A61P 3/04A61P 25/28A61P 27/02A61P 25/16A61P 25/18A61P 25/30A61P 25/00A61P 11/06C12Q 1/6883A61K 38/00A61P 15/08A61P 17/00C07K 14/47A61P 15/16A61P 13/12A61P 17/06A61P 19/02A61P 19/10A61P 21/04G01N 33/6893A61P 17/02
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to 87 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Claims

exact text as granted — not AI-modified
1 . An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of: 
 (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;    (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;    (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;    (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;    (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;    (f) a polynucleotide which is a variant of SEQ ID NO:X;    (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;    (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y,    (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.    
     
     
         2 . The isolated nucleic acid molecule of  claim 1 , wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.  
     
     
         3 . The isolated nucleic acid molecule of  claim 1 , wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.  
     
     
         4 . The isolated nucleic acid molecule of  claim 1 , wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.  
     
     
         5 . The isolated nucleic acid molecule of  claim 2 , wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.  
     
     
         6 . The isolated nucleic acid molecule of  claim 3 , wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.  
     
     
         7 . A recombinant vector comprising the isolated nucleic acid molecule of  claim 1 .  
     
     
         8 . A recombinant host cell comprising the recombinant vector of  claim 7 .  
     
     
         9 . An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of: 
 (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;    (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;    (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;    (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;    (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;    (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;    (g) a variant of SEQ ID NO:Y;    (h) an allelic variant of SEQ ID NO:Y; or (i) a species homologue of the SEQ ID NO:Y.    
     
     
         10 . The isolated polypeptide of  claim 9 , wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.  
     
     
         11 . An isolated antibody that binds specifically to the isolated polypeptide of  claim 9 .  
     
     
         12 . A recombinant host cell that expresses the isolated polypeptide of  claim 9 .  
     
     
         13 . A method of making an isolated polypeptide comprising: 
 (a) culturing the recombinant host cell of  claim 12  under conditions such that said polypeptide is expressed; and    (b) recovering said polypeptide.    
     
     
         14 . The polypeptide produced by  claim 13 .  
     
     
         15 . A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of  claim 9 .  
     
     
         16 . A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of  claim 1 .  
     
     
         17 . A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising: 
 (a) determining the presence or absence of a mutation in the polynucleotide of  claim 1;  and    (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.    
     
     
         18 . A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising: 
 (a) determining the presence or amount of expression of the polypeptide of  claim 9  in a biological sample; and    (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.    
     
     
         19 . A method for identifying a binding partner to the polypeptide of  claim 9  comprising: 
 (a) contacting the polypeptide of  claim 9  with a binding partner; and    (b) determining whether the binding partner effects an activity of the polypeptide.    
     
     
         20 . The product produced by the method of  claim 19.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.